Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.

Pal R, Mendelson JE, Flower K, Garrison K, Yount G, Coyle JR, Galloway GP.

J Addict Med. 2015 Mar-Apr;9(2):130-5. doi: 10.1097/ADM.0000000000000107.

2.

Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.

Mooney LJ, Hillhouse MP, Thomas C, Ang A, Sharma G, Terry G, Chang L, Walker R, Trivedi M, Croteau D, Sparenborg S, Ling W.

J Addict Med. 2016 Jul-Aug;10(4):236-43. doi: 10.1097/ADM.0000000000000218.

3.

Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.

Schacht JP, Anton RF, Voronin KE, Randall PK, Li X, Henderson S, Myrick H.

Neuropsychopharmacology. 2013 Feb;38(3):414-22. doi: 10.1038/npp.2012.195. Epub 2012 Oct 3.

4.

OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.

Coller JK, Cahill S, Edmonds C, Farquharson AL, Longo M, Minniti R, Sullivan T, Somogyi AA, White JM.

Pharmacogenet Genomics. 2011 Dec;21(12):902-5. doi: 10.1097/FPC.0b013e32834c5445.

PMID:
21946895
5.

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.

Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, Leventhal AM, Shoptaw S, Heinzerling K, London ED, Miotto K.

Neuropsychopharmacology. 2015 Sep;40(10):2347-56. doi: 10.1038/npp.2015.83. Epub 2015 Mar 24.

6.

A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.

Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW.

Psychopharmacology (Berl). 2009 Jan;201(4):611-8. doi: 10.1007/s00213-008-1330-5. Epub 2008 Sep 16.

PMID:
18795264
7.

Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.

Setiawan E, Pihl RO, Benkelfat C, Leyton M.

Pharmacogenomics. 2012 Jul;13(10):1161-72. doi: 10.2217/pgs.12.99. Review.

PMID:
22909206
8.

Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP.

N Engl J Med. 2016 Mar 31;374(13):1232-42. doi: 10.1056/NEJMoa1505409.

9.

Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.

Ziauddeen H, Nestor LJ, Subramaniam N, Dodds C, Nathan PJ, Miller SR, Sarai BK, Maltby K, Fernando D, Warren L, Hosking LK, Waterworth D, Korzeniowska A, Win B, Richards DB, Vasist Johnson L, Fletcher PC, Bullmore ET.

Neuropsychopharmacology. 2016 Oct;41(11):2647-57. doi: 10.1038/npp.2016.60. Epub 2016 Apr 25. Erratum in: Neuropsychopharmacology. 2018 Mar;43(4):927.

10.

An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability.

Jayaram-Lindström N, Wennberg P, Beck O, Franck J.

Nord J Psychiatry. 2005;59(3):167-71.

PMID:
16195116
11.

Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.

Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, Gourevitch MN.

Addiction. 2015 Jun;110(6):1008-14. doi: 10.1111/add.12894. Epub 2015 Apr 5.

PMID:
25703440
12.

Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.

Runarsdottir V, Hansdottir I, Tyrfingsson T, Einarsson M, Dugosh K, Royer-Malvestuto C, Pettinati H, Khalsa J, Woody GE.

J Addict Med. 2017 May/Jun;11(3):197-204. doi: 10.1097/ADM.0000000000000297.

13.

A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.

Kohno M, Dennis LE, McCready H, Schwartz DL, Hoffman WF, Korthuis PT.

Drug Alcohol Depend. 2018 Nov 1;192:186-192. doi: 10.1016/j.drugalcdep.2018.07.045. Epub 2018 Sep 21.

14.

A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.

Vallender EJ, Rüedi-Bettschen D, Miller GM, Platt DM.

Drug Alcohol Depend. 2010 Jun 1;109(1-3):252-6. doi: 10.1016/j.drugalcdep.2010.01.005. Epub 2010 Feb 13.

15.
16.

Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.

Chamorro AJ, Marcos M, Mirón-Canelo JA, Pastor I, González-Sarmiento R, Laso FJ.

Addict Biol. 2012 May;17(3):505-12. doi: 10.1111/j.1369-1600.2012.00442.x. Review.

PMID:
22515274
17.

The μ-opioid receptor and treatment response to naltrexone.

Thorsell A.

Alcohol Alcohol. 2013 Jul-Aug;48(4):402-8. doi: 10.1093/alcalc/agt030. Epub 2013 Mar 29. Review.

PMID:
23543091
18.

Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.

Marks KR, Lile JA, Stoops WW, Glaser PE, Hays LR, Rush CR.

J Clin Psychopharmacol. 2016 Jun;36(3):213-21. doi: 10.1097/JCP.0000000000000488.

19.

A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.

Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PD, Nunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O'Brien CP.

Subst Abus. 2012;33(1):48-59. doi: 10.1080/08897077.2011.609438.

20.

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?

Nunes EV, Krupitsky E, Ling W, Zummo J, Memisoglu A, Silverman BL, Gastfriend DR.

J Addict Med. 2015 May-Jun;9(3):238-43. doi: 10.1097/ADM.0000000000000125.

Supplemental Content

Support Center